Retatrutide: Published Research Summary

Introduction

Retatrutide (LY3437943) is an investigational triple GIP receptor, GLP-1 receptor, and glucagon receptor agonist developed by Eli Lilly and Company. Its published-literature profile spans in vitro pharmacology, cryo-electron microscopy structural biology, phase 1 and phase 2 clinical trials across multiple populations, and early phase 3 data. This article provides a bibliographic summary of key published studies, with attribution and methodology description for each. It reports what investigators reported in primary publications and does not draw independent conclusions or constitute a meta-analysis.

Methodology Types in the Published Literature

Research on retatrutide spans several methodological approaches: in vitro receptor pharmacology characterizing binding affinity and agonist potency across the three target receptors; cryo-electron microscopy structural studies resolving molecular binding poses at each receptor–G protein complex; and preclinical in vivo studies in diet-induced obese rodent models — whose findings inform but are not directly extrapolable to human populations. The molecular basis for these findings is covered in detail in the retatrutide mechanism of action article. Phase 1 clinical studies characterized pharmacokinetics, pharmacodynamics, and safety in small populations. Phase 2 randomized controlled trials assessed the compound's profile in three distinct populations over 36- to 48-week treatment periods. Phase 3 trials under the TRIUMPH and TRANSCEND program names were registered in 2023 and have begun reporting results.

Summary of Key Published Studies

Coskun et al., 2022 — Discovery and Preclinical Characterization

Coskun, Urva, Roell, and colleagues reported the discovery and initial characterization of LY3437943 in Cell Metabolism in 2022 [1]. The paper described the molecule's design rationale — a GIP peptide backbone with modifications for triple receptor engagement and fatty acid acylation for albumin binding — and characterized its in vitro receptor pharmacology. In diet-induced obese mouse models, LY3437943 administration was associated with reductions in body weight and glycemic control markers exceeding those of a selective GLP-1R agonist at comparable GLP-1R-engaging doses, with the additional effects attributed to GCGR-mediated energy expenditure. Phase 1 single-ascending-dose data in the same paper characterized the pharmacokinetic profile as consistent with extended-interval administration.

Li et al., 2024 — Structural Biology

Li, Zhou, Cong, and colleagues published cryo-electron microscopy structures of retatrutide in complex with the GLP-1R–Gs, GIPR–Gs, and GCGR–Gs complexes in Cell Discovery in 2024 [2]. The authors described distinct binding geometries at each receptor complex and characterized residue-level interactions accounting for the observed potency asymmetry — including retatrutide's higher relative potency at GIPR compared with native GIP. This work provided atomic-resolution context for the compound's multi-receptor pharmacological profile.

Urva et al., 2022 — Phase 1b Multiple-Ascending-Dose Trial

Urva, Coskun, Loh, and colleagues reported results from a phase 1b, multicenter, double-blind, placebo-controlled, randomized, multiple-ascending-dose trial in The Lancet in 2022 [3], enrolling adults with type 2 diabetes across multiple dose cohorts. The authors reported a pharmacokinetic profile consistent with extended-interval dosing and dose-dependent changes in pharmacodynamic markers of receptor engagement. Safety and tolerability findings were described as consistent with the GLP-1 receptor agonist class. This constituted the first peer-reviewed multi-dose human clinical data for retatrutide.

Jastreboff et al., 2023 — Phase 2 Obesity Trial (NEJM)

Jastreboff, Kaplan, Frías, and colleagues reported results from a phase 2, double-blind, randomized, placebo-controlled trial in the New England Journal of Medicine in 2023 [4]. The trial enrolled adults with a body mass index of 30 or higher (or 27 to less than 30 with at least one weight-related condition) and randomized participants to once-weekly subcutaneous retatrutide across several dose levels or placebo for 48 weeks. The authors reported statistically significant mean reductions in body weight from baseline across all retatrutide dose groups compared with placebo at 48 weeks, with the magnitude differing by dose level. Gastrointestinal adverse events — nausea, diarrhea, and vomiting — were the most frequently reported, consistent with the GLP-1 receptor agonist class. The authors noted that body weight reductions had not appeared to plateau by week 48 in the highest dose group, characterizing this as warranting evaluation in longer-duration studies.

Rosenstock et al., 2023 — Phase 2 Type 2 Diabetes Trial (Lancet)

Rosenstock, Frías, Jastreboff, and colleagues reported results from a phase 2, randomized, double-blind, placebo and active-controlled, parallel-group trial in The Lancet in 2023 [5]. The trial enrolled adults with type 2 diabetes across multiple retatrutide dose groups, a dulaglutide active-control group, and a placebo group at US sites. Over a 36-week treatment period, the authors reported statistically significant mean reductions in HbA1c and greater mean reductions in body weight across retatrutide groups versus both placebo and active control. Gastrointestinal adverse events were among the most frequently reported findings. Glycemic control and body weight outcomes had not reached apparent plateau by 36 weeks in higher dose groups — an observation the authors noted as informative for the subsequent phase 3 program design.

Sanyal et al., 2024 — Phase 2a MASLD Trial (Nature Medicine)

Sanyal, Kaplan, Frías, Brouwers, and colleagues reported results from a phase 2a, randomized, placebo-controlled trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD), published in Nature Medicine in 2024 [6]. The 98-participant trial used liver fat assessed by MRI-PDFF as the primary endpoint at 24 weeks. The authors reported statistically significant mean relative reductions in liver fat from baseline in all retatrutide dose groups compared with placebo at 24 weeks, with magnitude varying by dose level. Secondary histological and biochemical endpoints were also reported. The authors characterized the findings as hypothesis-generating and identified larger confirmatory trials as the appropriate next step.

TRANSCEND-T2D-1, 2026 — Phase 3 Type 2 Diabetes Trial (Lancet)

The Lancet published results from the TRANSCEND-T2D-1 phase 3 trial in 2026 [7]. This double-blind, randomized trial (NCT06354660) evaluated retatrutide in adults with type 2 diabetes and inadequate glycemic control on diet and exercise alone, and constitutes the first phase 3 peer-reviewed publication for retatrutide. Phase 3 results from the TRIUMPH obesity program trials (NCT05929066) were registered and actively enrolling at the time of this writing.

Active Research Frontier

Retatrutide's published literature continues to expand across several dimensions. The relative pharmacological contribution of each receptor target (GIPR, GLP-1R, GCGR) to the effects observed in human clinical trials is a recognized priority for future mechanistic work, as receptor-selective dissection studies in humans have not yet appeared in the primary literature. Long-term cardiovascular outcomes represent a planned area of the development program; results from a dedicated cardiovascular outcomes trial had not been reported at the time of this writing.

Durability of glycemic and body weight effects beyond the 48-week phase 2 timeframes, and outcomes following treatment discontinuation, are among the questions that extended phase 3 data are designed to address. The MASLD phase 2a findings, while statistically significant at the primary endpoint, are positioned as hypothesis-generating, with larger confirmatory studies identified as the appropriate next step. Pediatric pharmacokinetics and safety data represent an additional area that clinical development programs typically address following pivotal adult trial completion. Related phase 2 clinical research in the GLP-1/incretin class is summarized in the cagrilintide published research article, which covers a complementary amylin/GLP-1 co-agonist approach. Research-grade retatrutide from SpartaLabs is available with third-party-verified purity documentation.

References

1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013

2. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10:77. PMID: 39019866. DOI: 10.1038/s41421-024-00700-0

3. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. DOI: 10.1016/S0140-6736(22)02033-5

4. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972

5. Rosenstock J, Frías JP, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X

6. Sanyal AJ, Kaplan LM, Frías JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2037-2048. DOI: 10.1038/s41591-024-03018-2

7. The Lancet. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00967-0

8. ClinicalTrials.gov. A study of retatrutide (LY3437943) in participants who have obesity or overweight (TRIUMPH-1). NCT05929066. Available at: https://clinicaltrials.gov/study/NCT05929066